International Stem Cell Corp., a California-based biotechnology company developing novel stem cell based therapies, today told investors that it will be presenting preliminary data from its IND-enabling study in Parkinson’s disease at the Society for Neuroscience annual meeting in San Diego, CA, on November 10th 2013.
The Society for Neuroscience is the world’s largest organization of scientists and clinicians dedicated to understanding the brain and nervous system. Over 30,000 attendees are expected at this year’s annual meeting, making it one of the largest scientific and medical conferences in the world.
ISCO’s Parkinson’s disease program uses human parthenogenetic neural stem cells (hPNSC) which are a novel therapeutic cellular product derived from the company’s proprietary histocompatible human pluripotent stem cells. hPNSC are self-renewing mulitpotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to differentiate into dopaminergic (DA) neurons and express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new opportunity for the treatment of Parkinson’s disease, especially in cases where current small molecule approaches fail to adequately control the symptoms.
For more information on International Stem Cell Corp. and its Parkinson’s disease program, visit www.internationalstemcell.com
Let us hear your thoughts: International Stem Cell Corp. Message Board